

Press Release



AXA Private Equity acquires Riemser Arzneimittel AG

Frankfurt, August 21, 2012. AXA Private Equity, the leading European diversified private equity firm, has acquired Riemser Arzneimittel AG (Riemser), an international specialty pharmaceutical company, headquartered in Greifswald, Germany.

AXA Private Equity has acquired the shareholdings of Riemser's founding Braun family and those of various minority stakeholders, including TVM Capital. The completion of the transaction remains subject to approval by the German competition authority.

Riemser operates internationally and has a primary focus on the sales, marketing and lifecycle management of pharmaceutical products for niche therapeutic markets with high medical need in the fields of Oncology, Anti-Infectives and Dermatology. In 2011, Riemser, which has around 500 employees on its payroll, posted sales revenues of approximately €100 million and continues to grow profitably.

Christof Naményi, Managing Director of AXA Private Equity, said: "Riemser Arzneimittel AG is characterized by an increasing strategic focus on specialist niche therapeutic markets and is successfully pursuing an international growth strategy. With our global network, we will be actively supporting the strategy of continued specialization and internationalization which has been pursued by our management."

Dr. Michael Mehler, CEO of Riemser, added: "We are delighted to have found in AXA Private Equity a strong partner with whom we can continue our growth strategy systematically. The measures adopted over the past few years – such as internationalization and the increased specialization and strengthening of our product portfolio in selected therapeutic areas – have been the right steps on our path towards a successful future."

ABOUT AXA PRIVATE EQUITY

AXA Private Equity is a world leader in private equity, with assets of \$28 billion managed or advised in Europe, North America and Asia. The company offers its investors a wide choice of funds covering the full range of asset classes: Funds of Funds (primary, early secondary and secondary), Direct Funds including Infrastructure, Small and Mid Market Enterprise Capital, Innovation & Growth, Co-Investment and Private Debt.

With offices in Paris, Frankfurt, New York, Singapore, Milan, London, Zurich, Vienna and Luxembourg AXA Private Equity is committed to supporting companies in their long term growth by providing access to its international network. AXA Private Equity sets great store by the regularity and quality of its reporting on the performance of its funds and the performance of the companies in its portfolio, as a service to its investors.

AXA Private Equity, Global Investments the European way
www.axaprivateequity.com

ABOUT RIEMSER ARZNEIMITTEL AG

RIEMSER Arzneimittel AG, headquartered in Greifswald, Germany, is a midsize specialty pharmaceutical company which markets its products in Germany and in 72 other countries. RIEMSER focuses principally on prescription-only human pharmaceuticals in selected therapeutic markets with high medical need, in particular Oncology, Anti-Infectives, Dermatology and Dental.

PRESS CONTACT PERSON FOR AXA PRIVATE EQUITY

HeadLand Consultancy

Ben Girdlestone

Tel: +44 207 3675 243

bgirdlestone@headlandconsultancy.co.uk

Daniel Kahn

Tel: +44 207 3675 247

dkahn@headlandconsultancy.co.uk

PRESS CONTACT PERSON FOR RIEMSER ARZNEIMITTEL AG

Claudia Kerber

Head of Communications

An der Wiek 7

17493 Greifswald-Insel Riems

Tel.: +49 3835 1 76 129

presse@riemser.de